Lancet Neurology Study Finds Riluzole Ineffective for SCA2

Riluzole was not found to improve patient outcomes living with spinocerebellar ataxia type 2 in a study published in the journal Lancet Neurology. The repurposed amyotrophic lateral sclerosis drug, which  produced no significant radiological improvements as well, was not associated with any serious adverse events during the double-blinded 45-patient trial.

According to Robert Herpen of Healio, “Participants given riluzole displayed no serious adverse effects, while four patients in placebo group reported serious negative events, including hepatic enzyme increase, fracture of external malleolus, rectorrhagia and depression. Overall, the incidence of adverse events was roughly equal among riluzole (16) and placebo (19) patients.”

Click here to read more.

(Source: Healio, February 7^th, 2022)
(Image: Freestock)